These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 18758819)

  • 1. In vitro effect of radiation, antibody to epidermal growth factor receptor and Docetaxel in human head and neck squamous carcinoma cells with mutant P53 and over-expressed EGFR.
    Laytragoon-Lewin N; Ustun H; Castro J; Friesland S; Ghaderi M; Lundgren J; Turesson I; Lewin F
    J Cancer Res Clin Oncol; 2009 Feb; 135(2):203-9. PubMed ID: 18758819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma.
    Nozawa H; Tadakuma T; Ono T; Sato M; Hiroi S; Masumoto K; Sato Y
    Cancer Sci; 2006 Oct; 97(10):1115-24. PubMed ID: 16984384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
    La Fleur L; Johansson AC; Roberg K
    PLoS One; 2012; 7(9):e44071. PubMed ID: 23049743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-radiation enhances the cytotoxicity of docetaxel in head and neck squamous cell carcinoma cells.
    Furuse S; Adachi M; Ijichi K; Ohta S; Torigoe S; Nakazawa M; Miura S; Mitsudo K; Tohnai I
    Oncol Rep; 2010 May; 23(5):1339-43. PubMed ID: 20372849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perspectives of combined radioimmunotherapy and anti-EGFR antibody therapy for the treatment of residual head and neck cancer.
    van Gog FB; Brakenhoff RH; Stigter-van Walsum M; Snow GB; van Dongen GA
    Int J Cancer; 1998 Jul; 77(1):13-8. PubMed ID: 9639387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy.
    Kumai T; Matsuda Y; Oikawa K; Aoki N; Kimura S; Harabuchi Y; Celis E; Kobayashi H
    Br J Cancer; 2013 Oct; 109(8):2155-66. PubMed ID: 24045666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel induced gene expression patterns in head and neck squamous cell carcinoma using cDNA microarray and PowerBlot.
    Yoo GH; Piechocki MP; Ensley JF; Nguyen T; Oliver J; Meng H; Kewson D; Shibuya TY; Lonardo F; Tainsky MA
    Clin Cancer Res; 2002 Dec; 8(12):3910-21. PubMed ID: 12473607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation.
    Alsahafi EN; Thavaraj S; Sarvestani N; Novoplansky O; Elkabets M; Ayaz B; Tavassoli M; Legends MF
    Cancer Lett; 2021 Feb; 498():80-97. PubMed ID: 33137407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis.
    Huang SM; Harari PM
    Clin Cancer Res; 2000 Jun; 6(6):2166-74. PubMed ID: 10873065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers.
    Herbst RS; Langer CJ
    Semin Oncol; 2002 Feb; 29(1 Suppl 4):27-36. PubMed ID: 11894011
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancement of Ad-p53 therapy with docetaxel in head and neck cancer.
    Yoo GH; Piechocki MP; Oliver J; Lonardo F; Zumstein L; Lin HS; Kim H; Shibuya TY; Shehadeh N; Ensley JF
    Laryngoscope; 2004 Nov; 114(11):1871-9. PubMed ID: 15510008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A patient-derived somatic mutation in the epidermal growth factor receptor ligand-binding domain confers increased sensitivity to cetuximab in head and neck cancer.
    Bahassi el M; Li YQ; Wise-Draper TM; Deng L; Wang J; Darnell CN; Wilson KM; Wells SI; Stambrook PJ; Rixe O
    Eur J Cancer; 2013 Jul; 49(10):2345-55. PubMed ID: 23578570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. XRP6258-induced gene expression patterns in head and neck cancer carcinoma.
    Yoo GH; Kafri Z; Ensley JF; Lonardo F; Kim H; Folbe AJ; Won J; Stevens T; Lin HS
    Laryngoscope; 2010 Jun; 120(6):1114-9. PubMed ID: 20513026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
    Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
    Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC).
    Cohen RB
    Cancer Treat Rev; 2014 May; 40(4):567-77. PubMed ID: 24216225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of molecular targeted therapy with radiation in head and neck cancer.
    Du Y; Peyser ND; Grandis JR
    Pharmacol Ther; 2014 Apr; 142(1):88-98. PubMed ID: 24280066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incorporation of Next-Generation Sequencing into Routine Clinical Care to Direct Treatment of Head and Neck Squamous Cell Carcinoma.
    Chau NG; Li YY; Jo VY; Rabinowits G; Lorch JH; Tishler RB; Margalit DN; Schoenfeld JD; Annino DJ; Goguen LA; Thomas T; Becker H; Haddad T; Krane JF; Lindeman NI; Shapiro GI; Haddad RI; Hammerman PS
    Clin Cancer Res; 2016 Jun; 22(12):2939-49. PubMed ID: 26763254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.